FDA approves BMS's (BMY.US) lung cancer drug repotrectinib.
According to reports, the FDA has approved the drug repotrectinib from Roche for the treatment of a type of non-small cell lung cancer.
According to reports, the FDA has approved Bristol-Myers Squibb's drug repotrectinib for the treatment of a type of non-small cell lung cancer. Media reported later on Wednesday that the drug has been approved. The agency accepted BMS's repotrectinib application in May. The pharmaceutical company is seeking approval for the use of the drug in the treatment of advanced or metastatic ROS1-positive non-small cell lung cancer. In 2022, BMS acquired Turning Point Therapeutics for $4.1 billion, thereby gaining access to the repotrectinib therapy.
Related Articles
FOUNDER HOLD (00418) spent HKD 258,000 on May 9th to repurchase 262,000 shares.
CEB BANK (06818): Mabo approved as Chief Risk Officer
On May 9th, Zhuzhou CRRC Times Electric (03898) spent 19.7 million Hong Kong dollars to repurchase 610,300 shares.
FOUNDER HOLD (00418) spent HKD 258,000 on May 9th to repurchase 262,000 shares.
CEB BANK (06818): Mabo approved as Chief Risk Officer
On May 9th, Zhuzhou CRRC Times Electric (03898) spent 19.7 million Hong Kong dollars to repurchase 610,300 shares.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
